Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

The Effects of Daytime Psilocybin Administration on Sleep: Implications for Antidepressant Action

D. Dudysová, K. Janků, M. Šmotek, E. Saifutdinova, J. Kopřivová, J. Bušková, BA. Mander, M. Brunovský, P. Zach, J. Korčák, V. Andrashko, M. Viktorinová, F. Tylš, A. Bravermanová, T. Froese, T. Páleníček, J. Horáček,

. 2020 ; 11 (-) : 602590. [pub] 20201203

Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc21001608

Serotonergic agonist psilocybin is a psychedelic with antidepressant potential. Sleep may interact with psilocybin's antidepressant properties like other antidepressant drugs via induction of neuroplasticity. The main aim of the study was to evaluate the effect of psilocybin on sleep architecture on the night after psilocybin administration. Regarding the potential antidepressant properties, we hypothesized that psilocybin, similar to other classical antidepressants, would reduce rapid eye movement (REM) sleep and prolong REM sleep latency. Moreover, we also hypothesized that psilocybin would promote slow-wave activity (SWA) expression in the first sleep cycle, a marker of sleep-related neuroplasticity. Twenty healthy volunteers (10 women, age 28-53) underwent two drug administration sessions, psilocybin or placebo, in a randomized, double-blinded design. Changes in sleep macrostructure, SWA during the first sleep cycle, whole night EEG spectral power across frequencies in non-rapid eye movement (NREM) and REM sleep, and changes in subjective sleep measures were analyzed. The results revealed prolonged REM sleep latency after psilocybin administration and a trend toward a decrease in overall REM sleep duration. No changes in NREM sleep were observed. Psilocybin did not affect EEG power spectra in NREM or REM sleep when examined across the whole night. However, psilocybin suppressed SWA in the first sleep cycle. No evidence was found for sleep-related neuroplasticity, however, a different dosage, timing, effect on homeostatic regulation of sleep, or other mechanisms related to antidepressant effects may play a role. Overall, this study suggests that potential antidepressant properties of psilocybin might be related to changes in sleep.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21001608
003      
CZ-PrNML
005      
20210126092811.0
007      
ta
008      
210105s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fphar.2020.602590 $2 doi
035    __
$a (PubMed)33343372
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Dudysová, Daniela $u National Institute of Mental Health, Klecany, Czechia. Third Faculty of Medicine, Charles University, Prague, Czechia.
245    14
$a The Effects of Daytime Psilocybin Administration on Sleep: Implications for Antidepressant Action. / $c D. Dudysová, K. Janků, M. Šmotek, E. Saifutdinova, J. Kopřivová, J. Bušková, BA. Mander, M. Brunovský, P. Zach, J. Korčák, V. Andrashko, M. Viktorinová, F. Tylš, A. Bravermanová, T. Froese, T. Páleníček, J. Horáček,
520    9_
$a Serotonergic agonist psilocybin is a psychedelic with antidepressant potential. Sleep may interact with psilocybin's antidepressant properties like other antidepressant drugs via induction of neuroplasticity. The main aim of the study was to evaluate the effect of psilocybin on sleep architecture on the night after psilocybin administration. Regarding the potential antidepressant properties, we hypothesized that psilocybin, similar to other classical antidepressants, would reduce rapid eye movement (REM) sleep and prolong REM sleep latency. Moreover, we also hypothesized that psilocybin would promote slow-wave activity (SWA) expression in the first sleep cycle, a marker of sleep-related neuroplasticity. Twenty healthy volunteers (10 women, age 28-53) underwent two drug administration sessions, psilocybin or placebo, in a randomized, double-blinded design. Changes in sleep macrostructure, SWA during the first sleep cycle, whole night EEG spectral power across frequencies in non-rapid eye movement (NREM) and REM sleep, and changes in subjective sleep measures were analyzed. The results revealed prolonged REM sleep latency after psilocybin administration and a trend toward a decrease in overall REM sleep duration. No changes in NREM sleep were observed. Psilocybin did not affect EEG power spectra in NREM or REM sleep when examined across the whole night. However, psilocybin suppressed SWA in the first sleep cycle. No evidence was found for sleep-related neuroplasticity, however, a different dosage, timing, effect on homeostatic regulation of sleep, or other mechanisms related to antidepressant effects may play a role. Overall, this study suggests that potential antidepressant properties of psilocybin might be related to changes in sleep.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Janků, Karolina $u National Institute of Mental Health, Klecany, Czechia. Third Faculty of Medicine, Charles University, Prague, Czechia.
700    1_
$a Šmotek, Michal $u National Institute of Mental Health, Klecany, Czechia. Third Faculty of Medicine, Charles University, Prague, Czechia.
700    1_
$a Saifutdinova, Elizaveta $u National Institute of Mental Health, Klecany, Czechia. Czech Technical University in Prague, Prague, Czechia.
700    1_
$a Kopřivová, Jana $u National Institute of Mental Health, Klecany, Czechia. Third Faculty of Medicine, Charles University, Prague, Czechia.
700    1_
$a Bušková, Jitka $u National Institute of Mental Health, Klecany, Czechia. Third Faculty of Medicine, Charles University, Prague, Czechia.
700    1_
$a Mander, Bryce Anthony $u Department of Psychiatry and Human Behavior, School of Medicine, Center for the Neurobiology of Learning and Memory, University of California, Irvine, Irvine, CA, United States.
700    1_
$a Brunovský, Martin $u National Institute of Mental Health, Klecany, Czechia. Third Faculty of Medicine, Charles University, Prague, Czechia.
700    1_
$a Zach, Peter $u National Institute of Mental Health, Klecany, Czechia.
700    1_
$a Korčák, Jakub $u National Institute of Mental Health, Klecany, Czechia.
700    1_
$a Andrashko, Veronika $u National Institute of Mental Health, Klecany, Czechia.
700    1_
$a Viktorinová, Michaela $u National Institute of Mental Health, Klecany, Czechia. Third Faculty of Medicine, Charles University, Prague, Czechia.
700    1_
$a Tylš, Filip $u National Institute of Mental Health, Klecany, Czechia. Third Faculty of Medicine, Charles University, Prague, Czechia.
700    1_
$a Bravermanová, Anna $u National Institute of Mental Health, Klecany, Czechia. First Faculty of Medicine, Charles University, Prague, Czechia.
700    1_
$a Froese, Tom $u Embodied Cognitive Science Unit, Okinawa Institute of Science and Technology Graduate University, Okinawa, Japan.
700    1_
$a Páleníček, Tomáš $u National Institute of Mental Health, Klecany, Czechia. Third Faculty of Medicine, Charles University, Prague, Czechia.
700    1_
$a Horáček, Jiří $u National Institute of Mental Health, Klecany, Czechia. Third Faculty of Medicine, Charles University, Prague, Czechia.
773    0_
$w MED00174597 $t Frontiers in pharmacology $x 1663-9812 $g Roč. 11, č. - (2020), s. 602590
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33343372 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210126092807 $b ABA008
999    __
$a ind $b bmc $g 1613949 $s 1121892
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 11 $c - $d 602590 $e 20201203 $i 1663-9812 $m Frontiers in pharmacology $n Front Pharmacol $x MED00174597
LZP    __
$a Pubmed-20210105

Find record

Citation metrics

Logged in users only

Archiving options